



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of Dreyer Gustomer No.: 051957 Berial No: 10/734,930

Filed: Dec, 12, 2003

For: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY

Group Art Unit: 1614

Examiner: Fay, Zohreh A.

Confirmation No.: 2241

INFORMATION DISCLOSURE STATEMENT

Attn: Information Disclosure Statement Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled **CALCIUM BLOCKERS TO TREAT PROLIVERATIVE VITREORETINOPATHY**, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 1 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

Each item of information contained in this Supplemental Disclosure

Statement was cited in a communication from a foreign patent office in a

counterpart foreign application not more than three (3) months prior to the filing

of this statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date:

3/2/06

Brent A. Johnson

Patent Agent

Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson Allergan, Inc. 2525 Dupont Drive, T2-7H Irvine, California 92623-9534

Tel: (714) 246-4348 Fax: (714) 246-4249

Data:

3/2/06

Tvarie of person mailing paper

Signature of person mailing pape

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

/	0	P	E 4	6
0	MAR	0 6	2006	8
/3				الظر

Sheet	1	of	2
	'_	. OI .	

LIST OF ARTICITED BY APPLICANT

ATTY. DOCKET: 17322CON2CIP (AP)	SERIAL NO.: 10/734,930	
APPLICANTS: Evan B. Dreyer	TITLE: CALCIUM BLOCKERS TO TREAT PROLIVERATIVE VITREORETINOPATHY	
FILING DATE: Dec. 12, 2003	GROUP: 1614	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	DA	5,527,810	6/18/1996	Ornstein			, , , , , , , , , , , , , , , , , , , ,
			FOREIGN P	ATENT DOCUMENTS			
		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
				•			Yes
				thor, Title, Date, Pertiner			·
	DB	Constable I: "Biological and Therapeutic Aspects of Proliferative Vitreoretinopathy" Japanese Journal of Ophthalmology, Vol. 31, No. 4, 1987, pgs. 513-520, XP008054876					
	DC	Uchida N. et al: "Glutamate Stimulates Proliferation of Retinal Pigment Epithelium and Its BFGF Expression Through NMDA Receptor Activation", Vol. 71, No. Suppl. 1, 20 March 1996, page 274P, XP008040806					
	DD	Murphy T L et al: "Migration of retinal pigment epithelium cells in vitro is regulated by protein kinase C", Experimental Eye Research, Vol. 60, No. 6, June 1995, pages 683-695, XP-002102540					
	DE	Uchida N. et al: "Gltamate-Stimulated Proliferation of Rat Retinal Pigment Epithelium: Through NMDA Receptor Activation and BFGF Expression", Investigative Ophthalmology & Visual Science, Vol. 37, No. 3, 21 April 1996, pages S388, XP008040803					
	DF	Sakamoto T et al: "Vitamin E Succinate Inhibits Proliferation and Migration of Retinal Pigment Epithelial Cells in Vitro-Therapeutic Implication for Proliferative Vitreoretinopathy", Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 234, No. 3, March 1996, XP008040829					
	DG	Hackett S. et al: Cyclic 3',5'-Adenosine Monophosphate Modulates Retinal Pigment Epithelial Cell Migration in Vitro", Vol. 104, No. 11, Nov. 1986, pgs. 1688-1692, XP008054877					
	DF	Epithelial Cell C 59	hemotaxis",	n of Protein Carboxy Ophthalmic Researd	ch, Vol. 20), No. 1, 198	8, pages 54-
	DG	Systems on Reti	inal Pigment	Pharmacological Mo t Epithelial Cell Attac trch, Vol. 14, No. 5, I	hment to	Extracellular	Matrix

EXAM	IN	IFR	
	IJΝ	ILN.	

DATE CONSIDERED _

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449



Sheet __2_ of __2_

ST OF AR∜CITED BY APPLICANT

ATTY. DOCKET: 17322CON2CIP (AP) TRADEMAN	SERIAL NO.: 10/734,930
APPLICANTS: Evan B. Dreyer	TITLE: CALCIUM BLOCKERS TO TREAT PROLIVERATIVE VITREORETINOPATHY
FILING DATE: Dec. 12, 2003	GROUP: 1614

Di	Kalloniatis M.:"Amino Acids in Neurotransmission and Disease", Journal of the American Optometric Assoc., Vol. 66, No. 12, Dec. 1995, pgs. 750-757, XP008053708
D	Solberg Y et al: "Treatment of Laser-Induced Retinal Injuries by Neuroprotection", SPIE, Vol. 2974, 1997, pgs. 158-165
D	Ishikawa S. et al: "Alteration of Glutamine Concentration in the Vitreous Humor in Patients with Proliferative Vitreoretinopathy", Current Eye Research, Vol. 14, No. 3, March 1995, pgs. 191-197, XP008053697
Di	Haberecht M. et al: "N-Methyl-D-Aspartate-Mediated Glutamate Toxicity in the Developing Rabbit Retina" Journal of Neuroscience Research, Vol. 47, No. 4, 15 Feb. 1997, pgs. 416-426, XP008040828
D	Uchida et al: "Glutamate-Stimulated Proliferation of Rat Retinal Pigment Epithelial Cells", European Journal of Pharmacology, Vol. 343, No. 2/3, 19 Feb. 1998, pgs. 265-273, XP008040812